Shire buys bowel disease drug rights from Pfizer
14th Jun 2016 13:16
(ShareCast News) - Shire has agreed to buy the rights to an experimental drug aimed at treating inflammatory bowel disease (IBD) from Pfizer. The PF-00547659 drug has been evaluated in over 700 patients in Phase 1 and 2 trials and Phase 3 trials are expected to begin after consultation with global h
Read moreShire wins FDA breakthrough therapy designation for two drugs
13th Jun 2016 12:32
(ShareCast News) - Shire has been given an encouraging green light by the US drug regulator for two potential rare disease treatments in its pipeline. The US Food and Drug Administration (FDA) has bestowed a 'breakthrough therapy designation' on two of Shire's investigational products: SHP621, an or
Read moreMonday broker round-up
6th Jun 2016 12:55
(ShareCast News) - Wolseley: JP Morgan reiterates neutral with a target price of 4100p. Cairn Energy: RBC reiterates sector perform with a 250p target. Shire: Jefferies reiterates buy with a target price of 6050p and Exane BNP Paribas stays at outperform. Cobham: JP Morgan keeps at neutral with a
Read moreShire completes combination with Baxalta
3rd Jun 2016 09:16
(ShareCast News) - Irish pharmaceuticals company Shire said on Friday that it has completed its $32bn takeover of US-based Baxalta. Shire said that it expects to deliver double-digit compound annual top-line growth, with over $20bn in annual projected revenue by 2020 and around 65% of total annual r
Read moreShire rated 'outperform' by Credit Suisse ahead of Baxalta tie-up
1st Jun 2016 19:02
(ShareCast News) - Credit Suisse has reiterated its 'outperform' rating on Shire Pharmaceuticals, along with a target of 5000p, ahead of its proposed $32 billion acquisition of Baxalta closing on 3 June. Shire's shares closed up about 2.8% at 4380p on Wednesday. Earlier this year, the pair announce
Read moreShire shareholders approve Baxalta merger
27th May 2016 09:07
(ShareCast News) - Shire's shareholders have approved the company's $32bn merger with US-based Baxalta Inc. The Dublin-based pharmaceuticals group said on Friday that 93.8% of its shareholders voted in favour of the deal, which is expected to complete on 3 June. Chief executive Flemming Ornskov sai
Read moreDefensives lead bounce in stocks
20th May 2016 19:03
(ShareCast News) - Defensive issues led the market's bounce higher at the end of the week, with those sectors which stood to gain the most from a vote by Britons to remain in the UK pacing gains on the top flight index. Although low inflation boosts consumers' spending power, it is of scant benefit
Read moreFriday broker round-up
20th May 2016 14:32
(ShareCast News) - Exova Group: Goldman Sachs reiterates buy with a 195p target. Grainger: Jefferies retains buy with a 215p target. Thomas Cook: JP Morgan keeps at neutral with a 90p target and Goldman Sachs reiterates sell with a target price of 72p. Serco Group: JP Morgan reiterates neutral wit
Read moreBroker tips: Coca-Cola HBC, Shire, Centamin
20th May 2016 13:04
(ShareCast News) - Beverage bottler Coca-Cola HBC shares jumped on Friday after Citigroup upgraded the stock to 'buy'. Analysts at Citigroup said the company's shares trade at a five-year peak discount to peers. While they acknowledged concerns - including a potential naira devaluation and rising s
Read moreSunday newspaper round-up: RBS, Shell, Cobham, BT, banks
15th May 2016 17:01
(ShareCast News) - Royal Bank of Scotland is examining a range of radical options to help speed the long-delayed separation and flotation of its Williams & Glyn subsidiary, including a potential divestment of its NatWest brand. Banking sources have indicated to the Sunday Telegraph that RBS and its
Read moreBroker tips: Interserve, Shire, Man Group
6th May 2016 12:12
(ShareCast News) - Numis has placed its rating and target price on Interserve 'under review' after the company highlighted contractual issues. Interserve said expectations for its UK construction division have taken a significant hit due to a further deterioration in its Glasgow energy from waste co
Read moreLiberum initiates Shire at 'buy' despite Baxalta
6th May 2016 09:48
(ShareCast News) - Liberum initiated coverage of Shire at 'buy' with a 4,700p price target. It said the performance of the shares since August last year suggests investors are clearly worried Baxalta is not the right deal, with concerns focused on haemophilia and tax. Shire is down 29% since the fi
Read moreDirectors dealings: Shire chief sells part of performance share award
3rd May 2016 15:37
(ShareCast News) - Shire chief Flemming Ornskov sold 3,111 out of a total of 10,942 American Depositary Receipts which vested on 2 May, the company said in a statement. The ADS are each equivalent to three ordinary shares in the company and granted to Ornskov as part of a performance share award. O
Read moreShire's Q1 earnings and revenue beat expectations
29th Apr 2016 12:10
(ShareCast News) - Pharmaceutical company Shire posted better-than-expected first-quarter revenue and earnings on Friday as it said its acquisition of US-based Baxalta was on track. In the three months to the end of March, total revenue was up 17% to $1.71bn, surpassing analysts' expectations of $1.
Read moreShire shareholders approve remuneration report, but only just
28th Apr 2016 14:25
(ShareCast News) - Shire shareholders voted to approve the pay of the drug maker's top directors on Thursday, but only just. At the annual general meeting in Dublin, 50.55% of shareholders voted to approve the directors' remuneration report. "We have engaged extensively with our major shareholders
Read more